A Study of Once Monthly Intravenous or Subcutaneous Mircera in Participants With Chronic Kidney Disease on Hemodialysis.
Status:
Completed
Trial end date:
2011-07-01
Target enrollment:
Participant gender:
Summary
This 2 arm study will compare the hemoglobin maintenance with once monthly methoxy
polyethylene glycol-epoetin beta (Mircera) administration versus epoetin beta or darbepoetin
alfa in participants with chronic kidney disease on hemodialysis. Participants will be
randomized to receive either monthly intravenous (IV) or subcutaneous (SC) methoxy
polyethylene glycol-epoetin beta (at a starting dose of 120 or 200 micrograms, calculated
from the last weekly dose of epoetin beta or darbepoetin alfa previously administered), or
standard therapy (IV or SC epoetin beta once, twice or thrice weekly, or IV or SC darbepoetin
alfa once a week or twice a week).